Silence Therapeutics Investor Relations Material
Latest events
Q4 2024
Silence Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Silence Therapeutics plc
Access all reports
Silence Therapeutics plc is a biotechnology company that focuses on the discovery and development of therapeutic molecules using RNA interference (RNAi) technology. The company’s proprietary mRNAi GOLD platform is designed to develop short interfering RNA (siRNA) therapies that target and silence specific genes associated with various diseases, particularly in the liver. Silence Therapeutics is involved in developing treatments for cardiovascular conditions, hematological disorders, and rare diseases. Their leading product candidates include Zerlasiran (SLN360) for cardiovascular disease and Divesiran (SLN124) for hematological conditions. Silence Therapeutics plc is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SLN
Country
🇺🇸 United States